AEG-1/MTDH Orchestrates Angiogenesis in Hepatocellular Carcinoma Beyond VEGF Pathways
Background
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, characterized by extensive vascularization and aggressive progression. Angiogenesis is crucial for HCC development, supporting tumor growth, metabolic adaptation, and metastasis. While anti-angiogenic therapies targeting the vascular endothelial growth factor (VEGF) pathway have improved clinical management, their survival benefits are modest due to compensatory signaling and adaptive resistance. This highlights a critical gap, necessitating the exploration of novel, multi-targeted approaches beyond conventional VEGF-centric strategies to overcome therapeutic limitations.
Study Design
This review systematically synthesizes current literature on Astrocyte elevated gene-1/metadherin (AEG-1/MTDH)'s multifaceted role in Hepatocellular carcinoma (HCC) angiogenesis. Researchers analyzed existing studies detailing its molecular mechanisms, interactions within the tumor microenvironment (TME), and contributions to anti-angiogenic resistance. The focus was on identifying interconnected angiogenic, inflammatory, metabolic, and immune-regulatory programs orchestrated by AEG-1/MTDH, highlighting its systems-level influence on tumor progression and potential as a therapeutic target.
Results
AEG-1/MTDH emerges as a multifunctional oncogene, orchestrating interconnected angiogenic, inflammatory, metabolic, and immune-regulatory programs within the hepatic tumor microenvironment. It regulates angiogenesis through multiple pathways, including modulation of VEGF-family signaling, activation of NF-κB, and influence on hypoxia-responsive pathways. Furthermore, AEG-1/MTDH impacts PI3K/AKT signaling, endothelial remodeling, and the translational control of various pro-angiogenic mediators. Emerging evidence also implicates AEG-1/MTDH in hypoxia adaptation, immune evasion, extracellular vesicle signaling, and metabolic reprogramming, underscoring its broad regulatory capacity.
AEG-1/MTDH functions as a systems-level regulator of HCC angiogenesis, integrating diverse biological programs that contribute to tumor growth and therapeutic resistance.
Key Findings
- AEG-1/MTDH is a multifunctional oncogene orchestrating angiogenesis in HCC.
- It regulates angiogenesis via
VEGF-familysignaling,NF-κBactivation, andPI3K/AKTpathways. - AEG-1/MTDH contributes to hypoxia adaptation, immune evasion, and metabolic reprogramming in HCC.
- Its role extends beyond conventional VEGF-centric angiogenesis, influencing multiple interconnected programs.
- Targeting AEG-1/MTDH offers a potential multi-targeted therapeutic strategy for HCC.
Why It Matters
This comprehensive review shifts the paradigm for Hepatocellular carcinoma (HCC) treatment by highlighting AEG-1/MTDH as a central, multi-functional oncogene beyond the conventional focus on VEGF. For clinicians and researchers, understanding AEG-1/MTDH's role opens avenues for developing multi-targeted therapeutic strategies that could overcome current anti-angiogenic resistance and improve patient outcomes. Targeting AEG-1/MTDH could lead to more effective, durable responses by simultaneously disrupting multiple pro-angiogenic, inflammatory, and metabolic pathways. This moves us closer to designing combination therapies that address the complex nature of the tumor microenvironment, offering a more robust approach than single-pathway inhibition.
hepatocellular-carcinoma
hcc
angiogenesis
aeg-1
mtdh
oncogene